Advertisement

Immunologic Research

, Volume 50, Issue 2–3, pp 276–285 | Cite as

Targeting myeloid regulatory cells in cancer by chemotherapeutic agents

  • Hiam Naiditch
  • Michael R. Shurin
  • Galina V. Shurin
UNIVERSITY OF PITTSBURGH IMMUNOLOGY 2011

Abstract

Recent findings in humans and numerous experimental models provide evidence of the important role of immune regulatory cells in cancer and various diseases. “Myeloid regulatory cells” (MRC) include myeloid-derived suppressor cells, regulatory dendritic cells, regulatory macrophages, and subsets of granulocytes that expand during pathologic conditions and that have the ability to suppress cellular immunity. A decrease in MRC population and/or activity has been shown to have positive immune-potentiating effects. Several clinical trials have thus been initiated with the goal of manipulating the expansion or activation of these cells and thereby improving patient immune responses. New data from our own and other laboratories recently revealed that ultralow noncytotoxic doses of certain chemotherapeutic drugs could up-regulate antitumor immunity by modulating the formation, differentiation, and/or function of MRC. This new phenomenon, termed “chemomodulation,” allows for the regulation of the tumor microenvironment without the undesirable toxic effects associated with conventional chemotherapy. However, further studies are required before this new targeted therapy can find its way to patients with cancer.

Keywords

Myeloid-derived suppressor cells Dendritic cells Chemotherapy Chemomodulation 

References

  1. 1.
    Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med. 2006;12(8):875–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008;68(8):2561–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Ko JS, Bukowski RM, Fincke JH. Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep. 2009;11(2):87–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499–506.PubMedCrossRefGoogle Scholar
  5. 5.
    Lin A, et al. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett. 2010;127:7–84.CrossRefGoogle Scholar
  6. 6.
    Nagaraj S, et al. Regulatory myeloid suppressor cells in health and disease. Cancer Res. 2009;69(19):7503–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Suzuki E, et al. Gemcitabine selectively eliminates splenic Gr-1 +/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Ugel S, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol. 2009;9(4):470–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Kusmartsev S, et al. Antigen-specific inhibition of CD8 + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989–99.PubMedGoogle Scholar
  11. 11.
    Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8 + T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005;175(7):4583–92.PubMedGoogle Scholar
  12. 12.
    Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother. 2006;55(3):237–45.PubMedCrossRefGoogle Scholar
  13. 13.
    Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13(18 Pt 1):5243–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Ribechini E, et al. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol. 2010;199(3):273–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 2009;69(13):5514–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Huang B, et al. Gr-1 + CD115 + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang R, et al. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1 + CD11b + myeloid cells. Cancer Res. 2006;66(13):6807–15.PubMedCrossRefGoogle Scholar
  18. 18.
    Hoechst B, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135(1):234–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Rodriguez PC, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Poschke I, et al. Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83 and DC-sign. Cancer Res. 2010;70(11):4335–45.PubMedCrossRefGoogle Scholar
  21. 21.
    Youn JI, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–802.PubMedGoogle Scholar
  22. 22.
    Haile LA, et al. CD49d Is a New Marker for Distinct Myeloid-Derived Suppressor Cell Subpopulations in Mice. J Immunol. 2010;185(1):203–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Umemura N, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83(5):1136–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Dolcetti L, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40(1):22–35.PubMedCrossRefGoogle Scholar
  25. 25.
    Gallina G, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8 + T cells. J Clin Invest. 2006;116(10):2777–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Shurin MR, et al. Regulatory dendritic cells: New targets for cancer immunotherapy. Cancer Biol Ther. 2011; 11:11 (in press).Google Scholar
  27. 27.
    Sato K, et al. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood. 2003;101(9):3581–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Sato K, et al. Naturally occurring regulatory dendritic cells regulate murine cutaneous chronic graft-versus-host disease. Blood. 2009;113(19):4780–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Cook CH, et al. Spontaneous renal allograft acceptance associated with “regulatory” dendritic cells and IDO. J Immunol. 2008;180(5):3103–12.PubMedGoogle Scholar
  30. 30.
    Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2001;2(8):725–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Isomura I, et al. Induction of regulatory dendritic cells by topical application of NF-kappaB decoy oligodeoxynucleotides. Immunol Lett. 2008;119(1–2):49–56.PubMedCrossRefGoogle Scholar
  32. 32.
    Kojo S, et al. Induction of regulatory properties in dendritic cells by Valpha14 NKT cells. J Immunol. 2005;175(6):3648–55.PubMedGoogle Scholar
  33. 33.
    Torisu M, et al. Protective role of interleukin-10-producing regulatory dendritic cells against murine autoimmune gastritis. J Gastroenterol. 2008;43(2):100–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Fujita S, et al. Regulatory dendritic cells protect against allergic airway inflammation in a murine asthmatic model. J Allergy Clin Immunol. 2008;121(1):95–104 e7.PubMedCrossRefGoogle Scholar
  35. 35.
    Zhang M, et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol. 2004;5(11):1124–33.PubMedCrossRefGoogle Scholar
  36. 36.
    Norian LA, et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8 + T cell function via l-arginine metabolism. Cancer Res. 2009;69(7):3086–94.PubMedCrossRefGoogle Scholar
  37. 37.
    Liu Q, et al. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol. 2009;182(10):6207–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Dumitriu IE, et al. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4 + CD25 + Foxp3 + regulatory T cells. J Immunol. 2009;182(5):2795–807.PubMedCrossRefGoogle Scholar
  39. 39.
    Hutchinson JA, et al. Human regulatory macrophages. Methods Mol Biol. 2011;677:181–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Caso R, et al. Blood monocytes from mammary tumor-bearing mice: early targets of tumor-induced immune suppression? Int J Oncol. 2010;37(4):891–900.PubMedGoogle Scholar
  41. 41.
    Torroella-Kouri M, et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 2009;69(11):4800–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Edwards JP, Zhang X, Mosser DM. The expression of heparin-binding epidermal growth factor-like growth factor by regulatory macrophages. J Immunol. 2009;182(4):1929–39.PubMedCrossRefGoogle Scholar
  43. 43.
    Sinha P, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179(2):977–83.PubMedGoogle Scholar
  44. 44.
    Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756–60.PubMedGoogle Scholar
  45. 45.
    Brandau S, et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol. 2011;89(2):311–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Peranzoni E, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22(2):238–44.PubMedCrossRefGoogle Scholar
  47. 47.
    Ozao-Choy J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514–22.PubMedCrossRefGoogle Scholar
  48. 48.
    Suzuki E, et al. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther. 2007;6(6):880–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Vincent J, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Bunt SK, et al. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol. 2009;85(6):996–1004.PubMedCrossRefGoogle Scholar
  51. 51.
    Corzo CA, et al. HIF-1{alpha} regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010.Google Scholar
  52. 52.
    Narita Y, et al. Potential differentiation of tumor bearing mouse CD11b + Gr-1 + immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed Res. 2009;30(1):7–15.PubMedCrossRefGoogle Scholar
  53. 53.
    Greifenberg V, et al. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol. 2009;39(10):2865–76.PubMedCrossRefGoogle Scholar
  54. 54.
    Pan PY, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111(1):219–28.PubMedCrossRefGoogle Scholar
  55. 55.
    Sinha P, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181(7):4666–75.PubMedGoogle Scholar
  56. 56.
    Lechner MG, Liebertz DJ, Epstein AL, Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185(4): 2273–84.PubMedCrossRefGoogle Scholar
  57. 57.
    Marigo I, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity. 2010;32(6):790–802.PubMedCrossRefGoogle Scholar
  58. 58.
    Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24(2):96–102.PubMedCrossRefGoogle Scholar
  59. 59.
    Eruslanov E, et al. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J Leukoc Biol.Google Scholar
  60. 60.
    Lindenberg JJ, et al. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy. 2011;3(1):77–96.PubMedCrossRefGoogle Scholar
  61. 61.
    Greten TF, et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4 + T-cell responses in patients with advanced HCC. J Immunother. 2010;33(2):211–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Park JY, et al. Doxorubicin enhances CD4(+) T-cell immune responses by inducing expression of CD40 ligand and 4–1BB. Int Immunopharmacol. 2009;9(13–14):1530–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Le HK, et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol. 2009;9(7–8):900–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Kaneno R, et al. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med. 2009;7:58.PubMedCrossRefGoogle Scholar
  65. 65.
    Emens LA. Chemoimmunotherapy. Cancer J. 2011;16(4):295–303.CrossRefGoogle Scholar
  66. 66.
    Salem ML, et al. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol. 2010;184(4):1737–47.PubMedCrossRefGoogle Scholar
  67. 67.
    Diaz-Montero CM, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.PubMedCrossRefGoogle Scholar
  68. 68.
    Tseng CW, et al. Pretreatment with cisplatin enhances E7-specific CD8 + T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res. 2008;14(10):3185–92.PubMedCrossRefGoogle Scholar
  69. 69.
    Zhong H, et al. Low-dose Paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res. 2007;13(18):5455–62.PubMedCrossRefGoogle Scholar
  70. 70.
    Rossner S, et al. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol. 2005;35(12):3533–44.PubMedCrossRefGoogle Scholar
  71. 71.
    Zhou Z, et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells. 2010;28(3):620–32.PubMedGoogle Scholar
  72. 72.
    George S. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep. 2007;9(4):323–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Ko JS, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70(9):3526–36.PubMedCrossRefGoogle Scholar
  74. 74.
    Kao J, et al., Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol.Google Scholar
  75. 75.
    Nagaraj S, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2007;16(6):1812–23.CrossRefGoogle Scholar
  76. 76.
    Capuano G, et al. Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol. 2009;10:1.PubMedCrossRefGoogle Scholar
  77. 77.
    Ghosh N, et al. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 62(2): 233–244.Google Scholar
  78. 78.
    Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 2004;31((2 Suppl 7)):2–11.PubMedCrossRefGoogle Scholar
  79. 79.
    Dhawan D, et al. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther. 9(5): 1371–1377.Google Scholar
  80. 80.
    Li S, et al. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells. Cancer Invest. 2008;26(4):333–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Ashok V, et al. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast.Google Scholar
  82. 82.
    Apetoh L, et al. Harnessing dendritic cells in cancer. Semin Immunol. 2011;23(1):42–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Shurin GV, Amina N, Shurin MR. Cancer therapy and dendritic cell immunomodulation. In: Shurin MR, Salter RD, editors. Dendritic cells in cancer, New York: Springer; 2009. p. 201–216.Google Scholar
  84. 84.
    Wada S, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009;69(10):4309–18.PubMedCrossRefGoogle Scholar
  85. 85.
    Radojcic V, et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010;59(1):137–48.PubMedCrossRefGoogle Scholar
  86. 86.
    Salem ML, El-Naggar SA, Cole DJ. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol. 2010;261(2):134–43.PubMedCrossRefGoogle Scholar
  87. 87.
    Pfannenstiel LW, et al. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol. 2010;263(1):79–87.PubMedCrossRefGoogle Scholar
  88. 88.
    Byrd-Leifer CA, et al. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol. 2001;31(8):2448–57.PubMedCrossRefGoogle Scholar
  89. 89.
    Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother. 2000;49(4–5):181–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Kalechman Y, et al. The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. J Immunol. 1996;156(3):1101–9.PubMedGoogle Scholar
  91. 91.
    Manthey CL, et al. Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol. 1994;152(2):825–31.PubMedGoogle Scholar
  92. 92.
    Shurin GV, et al. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009;183(1):137–44.PubMedCrossRefGoogle Scholar
  93. 93.
    Kodumudi KN, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16(18):4583–94.PubMedCrossRefGoogle Scholar
  94. 94.
    Burkhart CA, et al. Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Res. 1994;54(22):5779–82.PubMedGoogle Scholar
  95. 95.
    Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.PubMedCrossRefGoogle Scholar
  97. 97.
    Taieb J, et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol. 2006;176(5):2722–9.PubMedGoogle Scholar
  98. 98.
    Medina-Echeverz J, et al. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol. 2011;186(2):807–15.PubMedCrossRefGoogle Scholar
  99. 99.
    Pulaski HL, et al. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009;7:49.PubMedCrossRefGoogle Scholar
  100. 100.
    Gabrilovich DI, et al. Mechanism of immune dysfunction in cancer mediated by immature Gr-1 + myeloid cells. J Immunol. 2001;166(9):5398–406.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Hiam Naiditch
    • 1
  • Michael R. Shurin
    • 1
  • Galina V. Shurin
    • 1
  1. 1.Departments of Pathology and Immunology, Experimental PathologyUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations